Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer originating from the abdominal lining. Our study revealed that BAP1 could serve as a prognostic and predictive biomarker for immunotherapy in PeM.
An algorithm to identify cancer driver genes in individual cancer patients by measuring the influence of gene alterations on perturbing transcriptional networks.